News

MJFF Expands Fellowship Program for Movement Disorder Specialists

To better care for the growing number of people with Parkinson’s disease and their families, the Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program. The two-year fellowship supports medical centers in training a new generation of…

Neurorehabilitation Seen to Ease Disease Symptoms, Protect Neurons

A therapeutic mix of exercise, cognitive stimulation and social activity — known as environmental enrichment — eased Parkinson’s disease symptoms and protected brain cells in a mouse model, though to a greater extent in early disease stages, a study reported. Benefits were notably less potent in animals with more advanced…

Generic Rotigotine Transdermal Patch Ready for Trial, XPhyto Says

XPhyto Therapeutics’ generic version of the Neupro patch for Parkinson’s disease is showing that its active ingredient, rotigotine, can be absorbed through the skin in ways similar to the brand-name product, the company announced. Findings, in work using skin from human cadavers and an optimized formula for the generic patch, support…

Former Parkinson’s Caregivers Could Help Those Now in That Role

Former caregivers could serve as a helpful resource in supporting current caregivers of people with Parkinson’s disease, a study reported. The intent is to “provide guidance for developing peer-to-peer support programs, incorporating former carers,” its researchers wrote. The study, “Using former carers’ expertise in peer support for…

Workshops at UAMS Target Neurodegenerative Disorders

The University of Arkansas for Medical Sciences (UAMS) is offering  complimentary vocal music workshops to patients with neurodegenerative disorders such as Parkinson’s disease. The workshops, which begin Oct. 26, will address patients’ physical, cognitive, and emotional needs, and are designed to teach patients how the voice works, how…

Potential Therapy FB-101 Well-tolerated in Healthy Volunteers

FB-101, an experimental oral therapy that 1ST Biotherapeutics is developing as a treatment for Parkinson’s disease, was well-tolerated in the first part of a Phase 1 clinical trial in healthy volunteers, the company announced. In the trial of (NCT04165837), which is being conducted in Baltimore,  24 adults…

Certain Nonmotor Symptoms Predict Anxiety In Parkinson’s

REM sleep behavior disorder (RBD) and autonomic dysfunction (dysautonomia), two types of nonmotor Parkinson’s disease symptoms, were significant predictors of anxiety in Parkinson’s patients over a three-year study. More than half (57%) of patients in in the study met the clinical criteria for anxiety at some point, underscoring its…